Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses - PubMed (original) (raw)
Review
Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses
Ludwig Deml et al. Mol Immunol. 2005 Feb.
Abstract
Several previous reports have clearly demonstrated the strong effectiveness of human immunodeficiency virus (HIV) Gag polyprotein-based virus-like particles (VLP) to stimulate humoral and cellular immune responses in complete absence of additional adjuvants. Yet, the mechanisms underlying the strong immunogenicity of these particulate antigens are still not very clear. However, current reports strongly indicate that these VLP act as "danger signals" to trigger the innate immune system and possess potent adjuvant activity to enhance the immunogenicity of per se only weakly immunogenic peptides and proteins. Here, we review the current understanding of how various particle-associated substances and other impurities may contribute to the observed immune-activating properties of these complex immunogens.
Similar articles
- Human immunodeficiency virus type-1 (HIV-1) Pr55gag virus-like particles are potent activators of human monocytes.
Speth C, Bredl S, Hagleitner M, Wild J, Dierich M, Wolf H, Schroeder J, Wagner R, Deml L. Speth C, et al. Virology. 2008 Dec 5;382(1):46-58. doi: 10.1016/j.virol.2008.08.043. Epub 2008 Oct 21. Virology. 2008. PMID: 18945465 - Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles.
Halsey RJ, Tanzer FL, Meyers A, Pillay S, Lynch A, Shephard E, Williamson AL, Rybicki EP. Halsey RJ, et al. Virus Res. 2008 May;133(2):259-68. doi: 10.1016/j.virusres.2008.01.012. Epub 2008 Mar 10. Virus Res. 2008. PMID: 18329748 - Further evidence for hexagonal organization of HIV gag protein in prebudding assemblies and immature virus-like particles.
Nermut MV, Hockley DJ, Bron P, Thomas D, Zhang WH, Jones IM. Nermut MV, et al. J Struct Biol. 1998 Oct;123(2):143-9. doi: 10.1006/jsbi.1998.4024. J Struct Biol. 1998. PMID: 9843668 - Virus-like particles: designing an effective AIDS vaccine.
Young KR, McBurney SP, Karkhanis LU, Ross TM. Young KR, et al. Methods. 2006 Sep;40(1):98-117. doi: 10.1016/j.ymeth.2006.05.024. Methods. 2006. PMID: 16997718 Review. - New understanding of immunological mechanisms.
Saalmüller A. Saalmüller A. Vet Microbiol. 2006 Oct 5;117(1):32-8. doi: 10.1016/j.vetmic.2006.04.007. Epub 2006 Apr 18. Vet Microbiol. 2006. PMID: 16701965 Review.
Cited by
- Digital Twin for Continuous Production of Virus-like Particles toward Autonomous Operation.
Hengelbrock A, Probst F, Baukmann S, Uhl A, Tschorn N, Stitz J, Schmidt A, Strube J. Hengelbrock A, et al. ACS Omega. 2024 Jul 25;9(32):34990-35013. doi: 10.1021/acsomega.4c04985. eCollection 2024 Aug 13. ACS Omega. 2024. PMID: 39157157 Free PMC article. - Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.
Tarrés-Freixas F, Clotet B, Carrillo J, Blanco J. Tarrés-Freixas F, et al. Vaccines (Basel). 2024 Mar 12;12(3):298. doi: 10.3390/vaccines12030298. Vaccines (Basel). 2024. PMID: 38543932 Free PMC article. Review. - Virus-like particle-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice.
Barajas A, Amengual-Rigo P, Pons-Grífols A, Ortiz R, Gracia Carmona O, Urrea V, de la Iglesia N, Blanco-Heredia J, Anjos-Souza C, Varela I, Trinité B, Tarrés-Freixas F, Rovirosa C, Lepore R, Vázquez M, de Mattos-Arruda L, Valencia A, Clotet B, Aguilar-Gurrieri C, Guallar V, Carrillo J, Blanco J. Barajas A, et al. J Transl Med. 2024 Jan 3;22(1):14. doi: 10.1186/s12967-023-04843-8. J Transl Med. 2024. PMID: 38172991 Free PMC article. - Gag Virus-like Particles Functionalized with SARS-CoV-2 Variants: Generation, Characterization and Recognition by COVID-19 Convalescent Patients' Sera.
Boix-Besora A, Gòdia F, Cervera L. Boix-Besora A, et al. Vaccines (Basel). 2023 Oct 26;11(11):1641. doi: 10.3390/vaccines11111641. Vaccines (Basel). 2023. PMID: 38005972 Free PMC article. - Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity.
Ortiz R, Barajas A, Pons-Grífols A, Trinité B, Tarrés-Freixas F, Rovirosa C, Urrea V, Barreiro A, Gonzalez-Tendero A, Cardona M, Ferrer L, Clotet B, Carrillo J, Aguilar-Gurrieri C, Blanco J. Ortiz R, et al. Int J Mol Sci. 2023 May 19;24(10):9025. doi: 10.3390/ijms24109025. Int J Mol Sci. 2023. PMID: 37240371 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources